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Takayuki Hashimoto, MD,* Nobuyoshi Fukumitsu, MD,* Ayako Ohkawa, MD,* Ayae Kanemoto, MD,*
Haruko Hashii, MD,* Toshiki Ohno, MD,* Takeji Sakae, PhD,* Koji Tsuboi, MD,*
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Introduction: This study was performed retrospectively to evaluate
the outcome of patients with stage III non-small cell lung cancer
(NSCLC) after proton beam therapy (PBT) alone.
Methods: The subjects were 57 patients with histologically con-
firmed NSCLC (stage IIIA/IIIB: 24/33) who received PBT without
concurrent chemotherapy. The cohort included 32 cases of squa-
mous cell carcinoma, 18 adenocarcinoma, and 7 non-small cell
carcinoma. Lymph node metastases were N0 7, N1 5, N2 30, and N3
15. Planned total doses ranged from 50 to 84.5 GyE (median, 74
GyE).
Results: Planned treatment was completed in 51 patients (89%). At
the time of analysis, 20 patients were alive, and the median fol-
low-up periods were 16.2 months for all patients and 22.2 months
for survivors. The median overall survival period was 21.3 months
(95% confidence interval: 14.2–28.4 months), and the 1- and 2-year
overall survival rates were 65.5% (52.9–78.0%) and 39.4% (25.3–
53.5%), respectively. Disease progression occurred in 38 patients,
and the 1- and 2-year progression-free survival rates were 36.2%
(23.1–49.4%) and 24.9% (12.7–37.2%), respectively. Local recur-
rence was observed in 13 patients, and the 1- and 2-year local
control rates were 79.1% (66.8–91.3%) and 64.1% (47.5–80.7%),
respectively. Grade 3 lung toxicity was seen in six patients,
esophageal toxicity occurred at grade 2, and there was no cardiac
toxicity.
Conclusion: The prognosis of patients with unresectable stage III
NSCLC is poor without chemotherapy. Our data suggest that high-
dose PBT is beneficial and tolerable for these patients.
Key Words: Proton, Non-small cell lung cancer, Advanced lung
cancer, Radiotherapy.
(J Thorac Oncol. 2012;7: 370–375)
Non-small cell lung cancer (NSCLC) is a common causeof cancer death worldwide.1 Surgery is recommended as
the first choice for curative local treatment. However, in most
cases, the disease is inoperable at the time of presentation
because of metastasis or a locally advanced unresectable
tumor. Many trials have shown a clinical benefit of concur-
rent chemoradiotherapy for the prognosis of patients with
locally advanced inoperable disease. However, improvement
of prognosis and reduction of side effects remains challeng-
ing, and previous clinical trials have often involved younger
patients or patients with a good performance status.2–6
Treatment for NSCLC has not been established in
elderly patients and patients with adverse prognostic factors
or comorbidities. Radiotherapy or chemotherapy alone has
been used for these patients, but the results of radiotherapy
alone with standard doses (60–66 Gy) are extremely poor.7–9
Proton beam therapy (PBT) gives superior dose localization
compared with conventional radiation and is therefore ex-
pected to deliver a high dose to the tumor with less toxicity.10
In our institution, PBT has been used for patients with
advanced lung cancer with the goals of reduced toxicity and
better local control.11,12 Herein, we report an analysis of 57
patients with unresectable stage III NSCLC who were treated
with PBT without concurrent chemotherapy.
PATIENTS AND METHODS
Patients
This study was conducted in accordance with the eth-
ical standards defined in the Declaration of Helsinki and was
approved by the ethics committee of the University of Tsu-
kuba. All patients provided written informed consent after a
comprehensive discussion covering the nature of their illness,
the therapeutic goal, other therapeutic options, and potential
adverse effects.
From 2001 to 2010, 57 patients with stage III NSCLC
(stage IIIA/IIIB, 24/33, male/female, 47/10) were treated
with PBT (Probeat; Hitachi, Tokyo, Japan) without concur-
rent chemotherapy. This report is based on data collected up
to March 31, 2011. Patient and tumor characteristics are
shown in Table 1. The median age of the patients was 72
*Department of Radiation Oncology, Tsukuba University and †Department of
Radiation Oncology, Tsukuba Medical Center Hospital, Ibaraki, Japan.
Disclosure: The authors declare no conflicts of interest.
Address for correspondence: Yoshiko Oshiro, MD, Department of Radiation
Oncology, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki
305-8575, Japan. E-mail: ooyoshiko@pmrc.tsukuba.ac.jp
Copyright © 2012 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/12/0702-0370
Journal of Thoracic Oncology • Volume 7, Number 2, February 2012370
years (range, 42–85 years), and 33, 20, and 4 patients had an
Eastern Cooperative Oncology Group performance status of
0, 1, and 2, respectively. Concurrent chemotherapy was not
performed due to old age, comorbidities (interstitial pneumo-
nitis [IP], chronic obstructive pulmonary disease, obstructive
pneumonitis, poor cardiac or lung function, cholangitis, dia-
betes, and dementia), and patient refusal for 23, 18, and 7
patients, respectively. Five of those 45 patients had induction
chemotherapy followed by PBT. In addition, nine other
patients had induction chemotherapy—in three the plan was
to be reconsidered for surgery after a potential response to
chemotherapy, and in six the initial tumor was deemed too
bulky for radiotherapy. However, there was no response
to chemotherapy in any of those patients. The fraction size
was 2.0 to 6.6 GyE (median, 2.0 GyE) given once daily, 5
days per week. A fraction size of 6.6 GyE was used for one
patient with a T4N0M0 tumor with vertebral body invasion.
The planned total doses were 50 to 84.5 GyE (median, 74
GyE), and the median value for the equivalent dose in 2.0 Gy
per fraction (assuming /  10) was 78.3 GyE. The cohort
included 32 cases of squamous cell carcinoma, 18 adenocar-
cinoma, and 7 non-small cell carcinoma. The lymph node
metastasis status was N0 7, N1 5, N2 30, and N3 15. Periodic
follow-up examinations were performed for 6 months after
the completion of PBT. Chest computed tomography (CT)
after PBT was taken at least once every 3 months for 2 years,
and once every 6 months thereafter. Adverse effects were
scored using the Common Terminology Criteria for Adverse
Effects, version 3.0.13
Proton Therapy
For treatment planning, chest CT images in 5-mm-thick
slices were obtained in the treatment position in a body cast
(Engineering System Co., Matsumoto, Japan) during the
end-expiratory phase using a respiratory-gaited system (Hi-
tachi). The clinical target volume (CTV) encompassed the
tumor volume (defined as the primary tumor), clinically
positive lymph nodes, and locoregional lymph nodes, plus a
margin of 5 to 10 mm in all directions. Prophylactic lymph
nodes were not included in the CTV. Clinically positive
lymph nodes were defined as nodes 1 cm visualized on a
CT scan or as positron emission tomography (PET)-positive
lymph nodes. PET scans were available in 35 patients. The
planned target volume covered the CTV with a 5-mm margin
in all directions and an additional 5-mm margin in the caudal
direction to compensate for respiratory motion.
Treatment was delivered through 200 MeV proton
beams during the end-expiratory phase using a respiratory
gating system, as described previously.13–21 The patient’s
body was immobilized using an individually shaped body
cast (ESFORM; Engineering System Co., Matsumoto, Ja-
pan). Respiratory gating was controlled using a laser range
finder that monitors the movement of the patient’s body
surface. The photon equivalent dose (Gray equivalent dose;
GyE) was defined as the physical dose (Gy)  the relative
biological effectiveness of the proton beam. Based on the
biological response of salivary gland tumor cells, the relative
biological effectiveness of the proton beam was assigned a
value of 1.1. Before each treatment, correct placement of the
patient relative to the radiation field was confirmed fluoro-
scopically. The treatment time was approximately 15 to 20
minutes for each fraction. Patients were routinely examined
once a week and the target volume was shrank due to tumor
shrinkage once (n  32), twice (n  11), and thrice (n  1)
in 44 patients.
Statistical Analysis
Actuarial survival and disease control rates were cal-
culated from the first day of treatment with PBT using the
Kaplan-Meier method. Progression-free survival was deter-
mined as the period from the beginning of PBT to the date of
relapse, as assessed by imaging according to the Response
Evaluation Criteria in Solid Tumors, or death. The local
control rate was calculated based on the time until the tumor
size increased by more than 20%. Differences in survival
were evaluated by log-rank test.22 A p value 0.05 was
considered to be statistically significant. All statistical anal-
yses were performed using commercially available software
(SPSS Inc., Chicago, IL).
RESULTS
Planned treatment was completed in 51 patients (89%).
The prescribed regimen could not be completed due to
TABLE 1. Patients and Tumor Characteristics (n  57)
Patients
Age (yr) 72 (42–85)
Sex
Male 47
Female 10
Performance status
0 33
1 20
2 4
Previous chemotherapy
yes 14
No 43
Tumors
Stage
IIIA 24
T2N2M0 19
T3N0M0 1
T3N1M0 1
T3N2M0 3
IIIB 33
T1N3M0 3
T2N3M0 3
T3N3M0 2
T4N0M0 6
T4N1M0 4
T4N2M0 8
T4N3M0 7
Pathology
Adenocarcinoma 18
Squamous carcinoma 32
Non-small cell carcinoma 7
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pneumonitis (three patients), disease progression (two pa-
tients), and technical problems (one patient). At the time of
analysis, 20 patients were alive, and the median follow-up
periods were 16.2 months for all patients and 22.2 months for
survivors. The median overall survival period was 21.3
months (95% confidence interval: 14.2–28.4 months), and the
overall survival rates at 1 and 2 years were 65.5% (52.9–
78.0%) and 39.4% (25.3–53.5%), respectively (Figure 1).
Stage (IIIB and IIIA), pathology, and previous chemotherapy
had no significant effect on overall survival (p  0.53, 0.14,
and 0.78, respectively). However, patients with N0,1 disease
had a better outcome than those with N2,3 disease (p 0.04).
Disease progression occurred in 38 patients. The pro-
gression-free survival rates at 1 and 2 years were 36.2%
(23.1–49.4%) and 24.9% (12.7–37.2%), respectively (Figure
2). Initial relapse sites were as follows: primary tumor or
lymph nodes within the field: 7, extrafield regional lymph
nodes: 4, primary tumor plus distant metastases: 2, distant
metastases only: 17, and intrapulmonary metastases: 8 (Table
2). Local recurrence was observed in 13 patients, and the 1-
and 2-year complete local control rates were 79.1% (66.8–
91.3%) and 64.1% (47.5–80.7%), respectively (Figure 3).
Acute and late toxicities are summarized in Tables 3
and 4, respectively. Acute esophageal toxicity was grade 2.
Grade 3 acute lung toxicity occurred in three patients. The
patient with grade 3 pneumonitis was treated effectively with
steroid therapy. One patient developed grade 4 pneumonitis
during treatment and had to discontinue treatment, and an-
other patient with severe died of pneumonitis during treat-
ment. These two patients had preexisting severe IP before
diagnosis of NSCLC and had taken oral steroid for the
disease. They were unable to undergo surgery and photon
FIGURE 1. Overall survival of all patients treated with pro-
ton beam therapy.
FIGURE 2. Progression-free survival of all patients treated
with proton beam therapy.
FIGURE 3. Local control for all patients treated with proton
beam therapy.
TABLE 2. Initial Site of Relapse
Sight
No. of
Patients
Primary tumor and lymph node within the field 7
Primary tumor  distant metastasis 2
Extra-field regional lymph node 4
Distant metastasis 17
Bone 6
Brain 2
Liver 1
Stomach 1
Multiple (bone, brain, liver, adrenal, muscle, abdominal
lymph nodes)
7
Intrapulmonary metastasis 8
TABLE 3. Early Toxicity (n  57)
Grade
0 1 2 3 4 5
Pneumonitis 49 1 4 1 1 1
Esophagitis 48 8 1 0 0 0
Cough 55 1 1 0 0 0
Dyspnea 57 0 0 0 0 0
Skin 36 16 5 0 0 0
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radiotherapy because of IP. The patients with grade 5 pneu-
monitis had received chemotherapy, but the disease had
progressed. Proton therapy was also challenging for these two
patients but was conducted in accordance with their strong
wishes. The median percentage of lung volume receiving 20
Gy (V20) and the mean lung dose were 15% and 7.9 GyE,
respectively, in all patients. V20s in the grade 4 and grade 5
patients were 10.5 and 20%, respectively, and mean lung
dose were 5.8 and 9.1 GyE, respectively, which were not
significantly higher than these values in other patients.
Late toxicity could be evaluated in 48 patients. Fibrotic
reactions in the treated regions were observed in follow-up
CT in every case. There was no cardiac toxicity. Two patients
developed grade 3 dyspnea and one case showed grade 5
hemoptysis; however, this patient had undergone repeated
biopsy of the irradiated bronchus.
DISCUSSION
Concurrent chemoradiotherapy has become the stan-
dard treatment for patients with locally advanced unresect-
able NSCLC.2–6 However, some patients cannot tolerate this
treatment because of its toxicity. These patients are treated
with radiotherapy alone, but their survival is extremely
poor.7–9 van Meerbeeck et al.23 reported a randomized study
comparing surgery versus radiotherapy of 66 Gy in 33 frac-
tions followed by induction chemotherapy in stage IIIA
patients and demonstrated that the mean survival time from
random assignment was 17.5 months for patients who re-
ceived radiotherapy. Also, Atagi et al.24 reported a random-
ized study comparing concurrent radiotherapy (60 Gy in 30
fractions) versus radiotherapy alone (60 Gy in 30 fractions)
for elderly patients (71 years) with stage III patients and
found that the mean survival time of patients treated by
radiotherapy alone was 14.2 months.
Recently, it has been proposed that more aggressive
local treatment can improve survival.6,25,26 Conformal 3D
radiotherapy enables delivery of higher doses to the tumor,
and favorable survival outcomes have been reported in many
dose escalation studies.6,25,27–31 With 74 Gy conformal radio-
therapy for stage III disease, Kong et al.31 obtained overall
survival rates at 2 and 3 years of 50 and 47%, respectively.
Yuan et al.29 also showed favorable results of dose escalation
and omission of elective nodal irradiation for inoperable stage
III disease, with delivery of 68 to 74 Gy with concurrent
chemotherapy giving 1-, 2-, and 5-year survival rates of 69.9,
39.4, and 25.1%. However, dose escalation is limited by the
high incidence of pulmonary and esophageal toxicity. The
frequency of effects on the esophagitis is influenced by
the length of the esophagus receiving 40 to 60 Gy,30 and
irradiation of large volumes and at high doses increases the
risk of pulmonary complications. Maguire et al.32 found
grade 3 esophagitis and late pulmonary toxicity in 15 and
17% of cases irradiated at 73.6 Gy, and Rosenman et al.30
FIGURE 4. Dose distribution (A, B,
C) and dose-volume histogram (D)
of proton beam therapy. A, Primary
tumor. B and C, The doses of
esophagus, heart, and lung were
reduced.
TABLE 4. Late Toxicity (n  48)
Grade
0 1 2 3 4 5
Dyspnea 41 2 3 2 0 0
Pneumonitis 44 1 3 0 0 0
Esophagitis 48 0 0 0 0 0
Skin 47 1 0 0 0 0
Hemoptysis 47 0 0 0 0 1
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reported that 8% of patients had grade 3 esophagitis after
irradiation at 66 to 74 Gy.
For most patients in the current study, chemotherapy
was not suitable or prior standalone chemotherapy had not
been effective. For 14 patients who did not respond to prior
chemotherapy, the prognosis was expected to be extremely
poor. However, our results for survival were better than those
for patients treated with radiotherapy alone or those who
responded to induction chemotherapy. Also, cases with se-
vere toxicity were less frequent than in other dose escalation
studies. These outcomes may have been due to dose escala-
tion, recent improvement of salvage treatment, and the ex-
cellent dose localization of PBT. Figure 4 shows the dose
distribution and dose-volume histogram for one patient. Us-
ing proton beams allowed the doses to the lung, esophagus,
and heart to be reduced.
Chang et al.33 compared dose-volume histograms in
patients with stage III NSCLC treated by photon therapy or
PBT and demonstrated that the doses to the normal tissue
were lower with PBT, compared with intensity modulated
radiotherapy, and that PBT could reduce the doses to the
lung, esophagus, and heart. In this study, elective nodal
irradiation was omitted, and the 1- and 2-year local control
rates were 79.1% (66.8–91.3%) and 64.1% (47.5–80.7%),
respectively. The first recurrence at extrafield regional lymph
nodes was observed in only four patients (7%). Recent
advances in imaging using PET have resulted in more precise
detection of lymph node metastases, and therefore we suggest
that omission of elective nodal irradiation is reasonable.
However, distant metastases is still a problem, and 31
(44.3%) of our patients had initial relapse with intrapulmo-
nary or distant metastases. This emphasizes the difficulty of
establishing an effective and less toxic systematic therapeutic
approach. However, taking into consideration that the prog-
nosis of patients with unresectable stage III NSCLC who
could not be treated with concurrent chemotherapy or who
did not respond to induction chemotherapy is expected to be
poor, we conclude that our data suggest that high-dose stand-
alone PBT is beneficial and tolerable for these patients.
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